The increased KAT7 in turn catalyzes H3K14ac and H3K12ac on its target gene promoters, facilitating transcriptions of oncogenic genes critical for GBM tumorigenesis and enhancing the response to anti-EGFR therapies. This evidence concerns the gene EGFR and glioblastoma.